U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06971185) titled 'A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept' on May 06.
Brief Summary: The purpose of this study is to understand the treatment patterns and clinical outcomes of myelodysplastic syndromes patients treated with luspatercept or erythropoiesis-stimulating agents
Study Start Date: Nov. 22, 2024
Study Type: OBSERVATIONAL
Condition:
Myelodysplastic Syndromes (MDS)
Intervention:
DRUG: Luspatercept
As per product label
DRUG: Erythropoiesis-stimulating agent (ESA)
As per product label
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Bristol-Myers Squibb
Disclaimer: Curated by HT Syndication....